Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
The drug sodium thiosulfate can protect the hearing of children with cancer undergoing treatment with the chemotherapy drug cisplatin, results from a new clinical trial show. The trial involved children with a form of liver cancer called hepatoblastoma.
-
Health care providers should emphasize cancer prevention when discussing HPV vaccination with the parents of preteens who are due to receive the vaccine, results from a new study show.
-
A new study has linked age with how well patients with melanoma responded to treatment with immune checkpoint inhibitors. Experiments in mice suggested that the response pattern may be due to an age-related shift in the kinds of immune cells in tumors.
-
Many in the cancer research and NIH community are mourning the loss of long-time NCI senior leader Alan Rabson, M.D., who passed away on July 4, at the age of 92. His career spanned 6 decades, including research on tumor virology and cancer pathology and senior NCI leadership roles.
-
The NCI Experimental Therapeutics (NExT) program works with researchers and top scientific experts to advance promising or novel cancer therapies from the earliest stages of research to human clinical trials.
-
Results from two clinical trials are expected to improve the outlook for some people with early-stage pancreatic cancer. Altering the chemotherapy drugs used and the timing of treatment substantially improved survival.
-
FDA expanded the approval of venetoclax (Venclexta) for people with chronic lymphocytic leukemia (CLL) to include those whose cancer has progressed after previous treatment, regardless of whether their cancer cells have the deletion 17p gene alteration.
-
Two studies examined the impact of more frequent follow-up testing for cancer recurrence in colorectal cancer survivors. Learn whether the studies showed that frequent testing improved survival.
-
As the patents on some widely used drugs to treat cancer expire in the coming years, biosimilar drugs are being developed for the treatment of patients with cancer. Are biosimilars effective and will they expand treatment options for patients?
-
This NCI-funded Children’s Oncology Group trial tested the addition of nelarabine (Arranon) to standard treatment for children and young adults with T-cell acute lymphoblastic leukemia (T-ALL).